Medications For Alcohol Use Disorder. DATE: October 10, 2017 PRESENTED BY: Alann Weissman-Ward, MD, Addiction Medicine fellow
|
|
- Leona McGee
- 5 years ago
- Views:
Transcription
1 Medications For Alcohol Use Disorder DATE: October 10, 2017 PRESENTED BY: Alann Weissman-Ward, MD, Addiction Medicine fellow
2 None DISCLOSURES
3 OBJECTIVES Be able to name 4 medications to treat AUD Describe contraindications and efficacy for each treatment Review which patients are appropriate for which treatment
4 PRIMARY REFERENCE SAMHSA TIP 49
5 ALCOHOL USE DISORDER MEDICATIONS 1. Oral Naltrexone 2. ER Naltrexone 3. Acamprosate 4. Disulfiram
6 ORAL NALTREXONE- 50 MG/DAY AVERAGE DOSE Approved for AUD in 1994 Metabolized by liver exclusively Still ~50% opioid blockade by 3 rd day without Marginal adherence, however can be taking prophylactically Mild effect on alcohol use, abstinence, craving
7 ORAL NALTREXONE Mechanism-competitively binds to endogenous opioid receptors and diminished pleasant sensation or high from alcohol and thought to decrease the motivational processes including reward anticipation and reinforcement
8 ORAL NALTREXONE Side effects Nausea May resemble prolonged alcohol withdrawal Rarely caused discontinuation in studies Risks Precipitated opioid withdrawal Hepatotoxicity Opioid Overdose Pregnancy category C
9 ORAL NALTREXONE Consider starting if LFTs < 5x upper limit normal AND no liver failure Urine drug screen negative for opioids 3-7 days since last drink At least 3 days since last opioid Challenge test if dependent on opioids Motivated or monitored patient
10 EXTENDED RELEASE (IM) NALTREXONE AKA VIVITROL Approved 2006 Bypasses first-pass liver metabolism Improved adherence (Bryson, 2011)
11 EXTENDED RELEASE (IM) NALTREXONE Side effects Nausea (hours) Site reactions Depressed mood Risks Precipitated opioid withdrawal Pain management issues Pregnancy category C Injection technique
12 EXTENDED RELEASE (IM) NALTREXONE Consider starting if Opioid free for 7-10 days days off buprenorphine/methadone Challenge test if dependent Comorbid OUD and AUD Trouble with adherence to daily dosing No anticipated surgery( 30 days following injection)or severe pain
13 Inpatients treated with naltrexone prior to discharge All cause 30 day readmissions decreased from 23% to 8% (p=0.04) All cause ED visits decreased from 19% to 6% (p=0.05) JGIM,
14 ACAMPROSATE 666MG TID ORAL DOSE Approved in 2004-similar in structure to GABA Limited effectiveness in US trials, but effective in European Trials Renal excretion 333mg tid for CrCl 30-50mL/min avoid in CKD stage 4-5, GFR less than 30
15 ACAMPROSATE Unclear mechanism of action-thought to help modulate/normalize ETOH related brain changes Calcium vs NMDA vs glutamate Kufahl, 2014 Unclear which groups to target for research Verheul, 2005
16 ACAMPROSATE Side effects Diarrhea-dose related, transient Self-limited HA, nausea, dizziness Depression No overdose risk No meaningful interactions Pregnancy category C
17 ACAMPROSATE Effects possibly influenced/mediated by AUD severity Large placebo Timing of initiation Length of detoxification Duration of use-the longer you take it the more beneficial
18 ACAMPROSATE Consider starting if Severe liver disease without renal impairment Highly motivated Recently completed detox (5 days) Opioid dependent Other bid-tid medications
19 COMBINATION NALTREXONE/ACAMPROSATE Initial study 1 : 160 patients N/A combination > A alone = N alone COMBINE 2 : 1383 patients, randomized to one of 9 interventions Slightly higher doses of N and A than typical N + counseling > placebo A = placebo PREDICT 3 : 426 patients, same format as COMBINE N = placebo; A = placebo 1:Kiefer 2003; 2: Anton, 2006; 3: Mann, 2013
20 DISULFIRAM (ANTABUSE): 250MG ONCE DAILY ORAL DOSE Approved 1951-Max dose 500 mg/day Aversive Poor adherence Can be mixed with methadone Pregnancy category C
21 DISULFIRAM: MECHANISM Blocks ALDH increased serum acetaldehyde sweating, dyspnea, vomiting, chest pain, vertigo, weakness Unpredictable severity Usually dose dependent 30 minute effect duration 2 week tail effect
22 DISULFIRAM Risks Death: rare Hepatotoxicity (1:25000) Dermatitis, acne Optic neuritis, peripheral neuritis Contraindications Severe CAD Active Psychosis Medication interactions Chlordiazepoxide, diazepam, warfarin, TCA, metronidazole
23 DISULFIRAM Consider starting if Blood/breath alcohol 0.00 Highly motivated Directly observed dosing Patient requesting it No severe CAD
24 AUD TX UNDER INVESTIGATION Varenicline Gabapentin Topiramate Valproate Nalmafene Baclofen Nalmefene
Medications For Alcohol Use Disorder
Medications For Alcohol Use Disorder PRESENTED BY: Alann Weissman-Ward, MD, Addiction Medicine fellow June 19, 2018 DISCLOSURES Speaker: Alann Weissman-Ward, MD, has nothing to disclose. Planning Committee:
More informationPharmacotherapy for Alcohol Use Disorder
Pharmacotherapy for Alcohol Use Disorder Laura G. Kehoe, MD, MPH Medical Director MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Disclosures Neither my
More informationPharmacotherapy for Alcohol Use Disorder
Pharmacotherapy for Alcohol Use Disorder Laura G. Kehoe, MD, MPH Medical Director MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Disclosures Neither my
More informationScreening, Diagnosis, and Medication Assisted Treatment for Alcohol Use Disorders
Psychiatry and Addictions Case Conference Screening, Diagnosis, and Medication Assisted Treatment for Alcohol Use Disorders MARK DUNCAN, MD Acting Assistant Professor, Co-lead University of Washington
More informationTreatment Alternatives for Substance Use Disorders
Treatment Alternatives for Substance Use Disorders Dean Drosnes, MD, FASAM Associate Medical Director Director, Chronic Pain and SUD Program Caron Treatment Centers 1 Disclosure The speaker has no conflict
More informationPharmacotherapy of Alcohol Use Disorders
Pharmacotherapy of Alcohol Use Disorders Roger D. Weiss, MD Professor of Psychiatry, Harvard Medical School Chief, Division of Alcohol and Drug Abuse McLean Hospital rweiss@mclean.harvard.edu Consultant
More informationLong term pharmacotherapy for Alcohol Dependence: Anti Craving agents
Long term pharmacotherapy for Alcohol Dependence: Anti Craving agents Myth or Reality? Complete Recovery means a medication-free state True or False? Treatment of Alcoholism Assessment Motivation Alcohol
More informationDr. Renner receives honoraria from Reed Medical Education
Substance Use Disorders Symposium on Men s Health Massachusetts Medical Society June 17, 2010 John A. Renner, Jr., M.D. John A. Renner Jr., MD DISCLOSURES Johnson & Johnson Stock Holder Dr. Renner receives
More informationAn Internist s Guide to Unhealthy Alcohol Use. Ryan Graddy, MD JHU SOM
An Internist s Guide to Unhealthy Alcohol Use Ryan Graddy, MD JHU SOM Disclosures None Learning Objectives Understand the terminology used to describe unhealthy alcohol use Identify means of screening
More informationTHE STATE OF MEDICINE IN ADDICTION RECOVERY
OVERVIEW: Review addiction stats and trends Define addiction Explain neurobiology of addiction Review treatments of addiction Addiction Definition: A Primary, chronic, relapsing disease of brain reward,
More informationMEDICATION ASSISTED TREATMENTS (MAT) FOR SUBSTANCE USE DISORDERS
MEDICATION ASSISTED TREATMENTS (MAT) FOR SUBSTANCE USE DISORDERS PHYLLIS RAYNOR, PHD, PMHNP-BC, APRN CLINICAL ASSISTANT PROFESSOR, USC COLLEGE OF NURSING LEARNING OBJECTIVES: Define types of SUD and purposes
More information8/5/2013. MOSBIRT Annual Training The Big change in addiction medicine? Before we dive into pharmacotherapy
Medication Assisted Treatment for Substance Abuse in Primary Care Dan Vinson August 1, 2013 1 The Big change in addiction medicine? These diseases are rapidly becoming medical diseases. Done are the days
More informationPharmacotherapy for Substance Use Disorders
Pharmacotherapy for Substance Use Disorders Vanessa de la Cruz, MD Chief of Psychiatry Mental Health and Substance Abuse Services Santa Cruz County Health Services Agency 1400 Emeline Avenue Santa Cruz,
More informationNALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018
NALTREXONE DAVID CRABTREE, MD, MPH TREATMENT OF OPIOID USE DISORDER (OUD) Majority of people who develop OUD are not receiving treatment Only a small fraction of patients are offered treatment with medications
More informationAlcohol 2: Case Examples
Alcohol 2: Case Examples Laura G. Kehoe, MD, MPH Medical Director, MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Disclosures Neither I nor my spouse/partner
More informationTHE NALTREXONE CHALLENGE
THE NALTREXONE CHALLENGE DISCLOSURE Natasha Rodney-Cail, Pharmacist, Drug Evaluation Unit Has no conflicts of interest Maureen Allen Has no conflicts of interest DONNA 68 years old Currently treated with
More informationMedication for the Treatment of Alcohol Use Disorder. Pocket Guide
Medication for the Treatment of Alcohol Use Disorder Pocket Guide Medications are underused in the treatment of alcohol use disorder. According to the National Survey on Drug Use and Health, of the estimated
More informationMedication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs
Medication Assisted Treatment Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs Disclosures Employed by the Department of Veterans Affairs
More informationAddiction Medicine: What s new for primary care
Addiction Medicine: What s new for primary care Dan Vinson, MD Family and Community Medicine How to talk so our patients listen, and listen so our patients talk. 1 2 Comfortably engaging your patient in
More informationNaltrexone protocol alcohol
P ford residence southampton, ny Naltrexone protocol alcohol The premier alcohol treatment program. Control or eliminate alcohol use using the Sinclair Method A Non 12-Step Outpatient Program. If you would
More informationMedication and Behavioral Treatment of Substance Use Disorders
Medication and Behavioral Treatment of Substance Use Disorders Brian Fuehrlein, MD, PhD Director, Psychiatric Emergency Room, VA Connecticut and Assistant Professor of Psychiatry, Yale University 1 Brian
More informationRiunione Monotematica AISF 2017 Roma 5 Ottobre Management of Alcohol Use Disorders in Patients with Alcoholic Liver Disease
Riunione Monotematica AISF 2017 Roma 5 Ottobre 2017 Management of Alcohol Use Disorders in Patients with Alcoholic Liver Disease Lorenzo Leggio, M.D., Ph.D., M.Sc. Lorenzo Leggio, M.D., Ph.D., M.Sc. Il
More informationKAP Keys. For Clinicians. Based on TIP 49 Incorporating Alcohol Pharmacotherapies Into Medical Practice. Knowledge Application Program
Incorporating Alcohol Pharmacotherapies Into Medical Practice Knowledge Application Program KAP Keys For Clinicians Based on TIP 49 Incorporating Alcohol Pharmacotherapies Into Medical Practice 49 U.S.
More informationTHE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept.
THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept. Public Health disclosures Dr. Martin has no conflict of interest to disclose.
More informationMedication Assisted Therapy Overview. ATTC Network s Third Thursday itraining Thomas E. Freese, Ph.D., Pacific Southwest ATTC February 17, 2011
Medication Assisted Therapy Overview ATTC Network s Third Thursday itraining Thomas E. Freese, Ph.D., Pacific Southwest ATTC February 17, 2011 Goals of the Training As a result of participating in this
More informationThaddeus Ulzen MD FRCP(C)FAPA FCGP Professor & Chair, Department of Psychiatry and Behavioral Medicine, Associate Dean for Academic Affairs
Thaddeus Ulzen MD FRCP(C)FAPA FCGP Professor & Chair, Department of Psychiatry and Behavioral Medicine, Associate Dean for Academic Affairs CCHS/University of Alabama School of Medicine Assessment History
More informationMedical Management of Substance Use Disorders: Does research translate to clinical practice
Medical Management of Substance Use Disorders: Does research translate to clinical practice Ashwin A Patkar, MD Professor of Psychiatry & Community & Family Medicine Duke University Medical Center Durham,
More informationQuick Guide. For Counselors. Based on TIP 49 Incorporating Alcohol Pharmacotherapies Into Medical Practice PHARMACO THERAPIES
Quick Guide For Counselors Based on TIP 49 Incorporating Alcohol Pharmacotherapies Into Medical Practice 49 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration
More informationPrepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry
Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry In broad terms, substance use disorders occur when a substance is used in a compulsive manner with a lack of control over
More informationMedication for Addiction Treatment (MAT)
SBIRT Training Screening, Brief Intervention & Referral to Treatment Medication for Addiction Treatment (MAT) The Faith & Spirituality Integrated SBIRT Network Navigating the Training Welcome! These health
More informationDr. Oslin receives grant support from the NIH, VA, and the Pennsylvania Department of Aging.
David W. Oslin, MD University of Pennsylvania Philadelphia VAMC Dr. Oslin receives grant support from the NIH, VA, and the Pennsylvania Department of Aging. Dr. Oslin is a consultant to the Hazelden Betty
More informationVarenicline and Other Pharmacotherapies for Tobacco Dependence
Varenicline and Other Pharmacotherapies for Tobacco Dependence J. Taylor Hays, M.D. Associate Director Nicotine Dependence Center Mayo Clinic 2012 MFMER slide-1 Learning Objectives Understand the mechanism
More informationALCOHOL USE DISORDER WITHDRAWAL MANAGEMENT AND LONG TERM TREATMENT ANA HOLTEY, MD ADDICTION MEDICINE FELLOW UNIVERSITY OF UTAH HEALTH
ALCOHOL USE DISORDER WITHDRAWAL MANAGEMENT AND LONG TERM TREATMENT ANA HOLTEY, MD ADDICTION MEDICINE FELLOW UNIVERSITY OF UTAH HEALTH Prevalence of 12-Month Alcohol Use, High-Risk Drinking, and DSM-IV
More informationDecreasing Alcohol Use with Medications: What Works?
Decreasing Alcohol Use with Medications: What Works? Annual Review of Family Medicine December 7 th, 2017, UCSF Mission Bay Ben Smith, MD MPH Assistant Professor of Family and Community Medicine San Francisco
More informationPage 1. Pharmacologic Interventions for. Addictions. Objectives for This Talk. Outline for This Talk
Pharmacologic Interventions for Addictions Eric C. Strain, M.D. Johns Hopkins University School of Medicine, Baltimore, Maryland Maryland Psychiatric Society November 7, 2015 Objectives for This Talk I.
More informationPharmacologic Interventions for. Addictions
Pharmacologic Interventions for Addictions Eric C. Strain, M.D. Johns Hopkins University School of Medicine, Baltimore, Maryland Maryland Psychiatric Society November 7, 2015 Objectives for This Talk I.
More informationMedication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users.
Slide #1 Medication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users. R. Douglas Bruce, MD, MA, MSc Assistant Professor Yale AIDS Program Medical Director South Central Rehabilitation
More informationAlcohol Use Disorder Medications. Kavara Vaughn, MD ECHO Lecture Series September 22, 2016
Alcohol Use Disorder Medications Kavara Vaughn, MD ECHO Lecture Series September 22, 2016 Drinking Levels De6ined At risk or heavy drinking Women > 3 drinks in a day OR > 7 drinks in a week Men > 4 drinks
More informationThe future of pharmacological treatment.
The future of pharmacological treatment. Anne Lingford-Hughes Professor of Addiction Biology, Imperial College. Hon Consultant CNWL NHS Foundation Trust. What substances and when? What Nicotine Alcohol
More informationMedication-Assisted Treatment (MAT) Overview
Medication-Assisted Treatment (MAT) Overview 2014 Opiate Conference: Don t Get Me Started Hyatt Regency, Columbus, Ohio June 30-July 1, 2014 Christina M. Delos Reyes, MD Medical Consultant, Center for
More information6B / Boswell, Grant and Slutske Day 2 August 14, 2008
Pharmacological Treatment of Pathological Gambling Jon E. Grant, JD, MD, MPH Associate Professor University of Minnesota School of Medicine Minneapolis, MN Disclosure Information I have the following financial
More informationMedical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center
Medical Assisted Treatment Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Current Trends Prescription Drug Abuse/Addiction Non-medical use of prescription pain killers
More informationLong term treatment for opioid dependence Antagonist therapy
Long term treatment for opioid dependence Antagonist therapy Treatment of Opioid Dependence Antagonist treatment Naltrexone Naltrexone (NTX) synthesized in 1965 Eliminate drug carving and prevent relapse
More informationMain Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders
Substance Use Disorders Main Questions Why study addiction? What is addiction? Why do people become addicted? What do alcohol and drugs do? How do we treat substance use disorders? Why study addiction?
More informationGuidance for naltrexone prescribing
Document level: Drug Alcohol (Trustwide) Code: DA7 Issue number: 2 Guidance for naltrexone prescribing Lead executive Authors details Type of document Target audience Document purpose Lead Clinical Director
More informationArwen Podesta, MD. ABIHM, ABAM, Forensic Psychiatry
The State of Medicine in Addiction Recovery Arwen Podesta, MD ABIHM, ABAM, Forensic Psychiatry www.podestawellness.com 504-252-0026 http://www.addictionpolicy.org/ Overview Addiction is a serious, chronic
More informationManagement of Unhealthy Alcohol Use: From Research to Practice
Management of Unhealthy Alcohol Use: From Research to Practice Richard Saitz MD, MPH, FACP, DFASAM Professor of Community Health Sciences & Medicine Boston University Schools of Medicine & Public Health
More informationMethadone and Naltrexone ER
Methadone and Naltrexone ER Laura G. Kehoe, MD, MPH, FASAM Medical Director MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Disclosures Neither I nor my
More informationMary Ann Ferguson,Pharmacist St Josephs Health Care Concurrent Disorders Inpatient Unit
Mary Ann Ferguson,Pharmacist St Josephs Health Care Concurrent Disorders Inpatient Unit Fergusom@stjoes.ca Medication should be considered as part of the treatment plan for addictions/substance use disorders:
More informationBiological Addictions Treatment. Psychology 470. Many Types of Approaches
Many Types of Approaches Biological Addictions Treatment Psychology 470 Introduction to Chemical Additions Steven E. Meier, Ph.D. Listen to the audio lecture while viewing these slides Detoxification approaches
More informationMAT in the Corrections Setting
MEDICATION ASSISTED TREATMENT AND CORRECTIONS Frank Filippelli, DO, PhD September 2017 MAT in the Corrections Setting Who Does This Affect? What is MAT and What is the Evidence of Efficacy? Emphasis on
More informationTreatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This fact sheet discusses research findings on effective treatment approaches for drug abuse and addiction. If you re seeking treatment, you can call the Substance
More informationTreatment Team Approaches in Substance Abuse Treatment
Treatment Team Approaches in Substance Abuse Treatment PLANT A SEED AND WATCH IT GROW 2 Substance use disorders span a wide variety of problems arising from substance use, and cover 11 different criteria:
More informationSubstance Use Disorders: What Can We Do to Help Break the Cycle of Addiction
Handout for the Neuroscience Education Institute (NEI) online activity: Substance Use Disorders: What Can We Do to Help Break the Cycle of Addiction Learning Objectives Identify patients who are dependent
More informationMedication-assisted Treatment for Alcohol and Opioid Use Disorders: Lessons from META:PHI
Medication-assisted Treatment for Alcohol and Opioid Use Disorders: Lessons from META:PHI Family Medicine Forum November 9, 2017 Meldon Kahan, MD Kate Hardy, MSW Sarah Clarke, PhD Presenter Disclosure
More informationThe Approach to the Functional Alcoholic
Friday General Session The Approach to the Functional Alcoholic Daniel Hochman, MD Psychiatrist, Private Practice Founder, Self Recovery LLC President, Texas Physicians for Social Responsibility Austin,
More informationTHE APPROACH TO THE FUNCTIONAL ALCOHOLIC
THE APPROACH TO THE FUNCTIONAL ALCOHOLIC Texas Academy of Family Physicians 2018 C. Frank Webber Lectureship Daniel Hochman, MD Speaker Disclosure Dr. Hochman has disclosed that he is owner and creator
More informationGOALS AND OBJECTIVES
SUBOXONE AND VIVITROL: ARE THERE DISPARITIES SURFACING IN MEDICATION ASSISTED TREATMENTS? P R E S E N T E D B Y D R. K I AM E M AH A N I A H & D R. M Y E C H I A M I N T E R - J O R D AN GOALS AND OBJECTIVES
More informationBuprenorphine for Family Medicine. Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17
+ Buprenorphine for Family Medicine Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17 + Disclosures No conflicts of interest Off-label use of medications + Who here: Has taken care of a patient
More informationClinical Guidelines and Procedures for the Use of Naltrexone in the Management of Opioid Dependence Abbreviated Version
Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of Opioid Dependence Abbreviated Version Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of
More informationManagement of Alcohol. Michael Tang DO
Management of Alcohol and Opioid Detox Michael Tang DO Disclosure Kaiser Permanente South San Francisco has determined that the speaker (Dr. Tang) and the planning committee (Dr. Becker, Dr. Shanteau,
More informationANTICONVULSANTS IN ALCOHOL WITHDRAWAL TREATMENT: A BETTER WAY?
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences ANTICONVULSANTS IN ALCOHOL WITHDRAWAL TREATMENT: A BETTER WAY? RICHARD RIES MD PROFESSOR OF PSYCHIATRY AND DIRECTOR
More informationSerious Mental Illness and Opioid Use Disorder
Serious Mental Illness and Opioid Use Disorder Serious Mental Illness and Opioid Use Disorders Arthur Robin Williams, MD MBE Columbia University, Department of Psychiatry Nick Szubiak, MSW, LCSW Director,
More informationFaculty Disclosures. Disclosures. Updates on the Long-Term Management of Opioid and Alcohol Use Disorders: A Focus on Medication-Assisted Treatment
Updates on the Long-Term Management of Opioid and Alcohol Use Disorders: A Focus on Medication-Assisted Treatment Supported by an educational grant from Alkermes, Inc. Rakesh Jain, MD, MPH Clinical Professor
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the
More informationDISCLAIMER. Original Effective Date: 6/23/14. Subject: Vivitrol (naltrexone for extended-release injectable suspension) Policy Number: MCP-177
Subject: Vivitrol (naltrexone for extended-release injectable suspension) Policy Number: MCP-177 Original Effective Date: 6/23/14 Revision Date(s): Review Date(s): 12/16/15; 9/15/2016; 6/22/2017 DISCLAIMER
More informationMethadone and Naltrexone ER
Methadone and Naltrexone ER Laura G. Kehoe, MD, MPH, FASAM Medical Director MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Objectives Review Full Opioid
More informationPrescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence)
Hull & East Riding Prescribing Committee Prescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence) Patients Name: Unit Number: Patients Address:.. G.P s Name:.. Communication We agree
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationPsychopharmacological Treatment of Substance Use Disorder(s) Alisha Moreland, M.D. Oregon Health & Science University
Psychopharmacological Treatment of Substance Use Disorder(s) Alisha Moreland, M.D. Oregon Health & Science University OBJECTIVES SBIRT Review of the reward pathway Pharmacologic Management of Alcohol Substance
More informationA Real Case. Substance Use Disorders in Primary Care: Screening, Brief Interventions, Pharmacotherapy. Quiz Your Clinic Panel
Substance Use Disorders in Primary Care: Screening, Brief Interventions, Pharmacotherapy Katherine Julian, M.D. UCSF Division of General Internal Medicine August 7, 2013 A Real Case 31 yo man presenting
More informationAlcoholism has been demonstrated to have a genetic component, especially among men.
Causes and Treatment of Substance-Related Disorders (Chapter 10) Familial and Genetic Influences Alcoholism has been demonstrated to have a genetic component, especially among men. Seems to be a common
More informationDRUGS USED IN THE TREATMENT OF ADDICTION JOSEPH A. TRONCALE, MD FASAM RETREAT PREMIERE ADDICTION TREATMENT CENTERS
DRUGS USED IN THE TREATMENT OF ADDICTION JOSEPH A. TRONCALE, MD FASAM RETREAT PREMIERE ADDICTION TREATMENT CENTERS MAJOR CATEGORIES OF TREATMENTS Detoxification and Post-Acute Withdrawal Maintenance Co-Occurring
More informationOpioid Use Disorders &Medication Treatment
Agency medical director comments Opioid Use Disorders &Medication Treatment Charissa Fotinos, MD, MSc Deputy Chief Medical Officer Washington State Health Care Authority Learning Objectives: 1) Review
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance
More informationAMBULATORY DETOXIFICATION In the 21 st Century
AMBULATORY DETOXIFICATION In the 21 st Century Louis E. Baxter, Sr., M.D., DFASAM, DABAM DMHAS-Addiction Medicine Consultant Executive Medical Director Professional Assistance Program of N J Clinical Assistant
More informationNURSING FOLLOW-UP: BUPRENORPHINE/NALOXONE BUPRENORPHINE/NALOXONE CLINIC VISITS
Provider Name: NURSING FOLLOW-UP: BUPRENORPHINE/NALOXONE Provider Signature: Date: BUPRENORPHINE/NALOXONE CLINIC VISITS Once stable, schedule clinic visits every 2 to 4 weeks, with refills that coincide
More informationPharmacotherapy for Addiction A Practical Guide
A Practical Guide Poll Everywhere Text: 22333 Message: ROBYNJORDAN620 Assistance Professor of Psychiatry UNC School of Medicine Sept 28, 2018 Disclosures None Poll Everywhere Text: 22333 Message: ROBYNJORDAN620
More informationCan We Stop Calling It, "Medication-Assisted Treatment"?
MNCAMH Webinar Can We Stop Calling It, "Medication-Assisted Treatment"? Anti-relapse Medications For Substance Use Disorders Ian McLoone, LPCC, LADC Agenda 1 2 3 4 5 The Importance of Language Neurobiology
More informationDiagnosis and treatment of alcohol use disorder in primary care
Diagnosis and treatment of alcohol use disorder in primary care Scott Steiger, MD, FACP, FASAM HS Associate Clinical Professor of Medicine and Psychiatry UCSF-ZSFG Disclosure No financial conflicts Trade
More informationVivitrol Vs. Suboxone
Vivitrol Vs. Suboxone Vivitrol - Naltrexone Indicated for opiate dependence and alcohol withdrawal pure antagonist 380mg once every 4 weeks IM Peak plasma concentration in 2 hrs, followed by a second peak
More informationEXTENDED-NALTREXONE for the Treatment of OPIOID USE DISORDER:
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences EXTENDED-NALTREXONE for the Treatment of OPIOID USE DISORDER: September 13, 2018 Matt Iles-Shih, MD Acknowledgement:
More informationManagement of high risk MMT patients. Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013
Management of high risk MMT patients Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013 CFPC CoI Templates: Slide 1 Faculty Disclosure Faculty: Meldon Kahan Relationships with commercial
More informationLONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE
LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE DR. SHILPA ADARKAR ASSOCIATE PROFESSOR DEPARTMENT OF PSYCHIATRY & DRUG DEADDICTION CENTRE OF EXCELLENCE SETH GSMC & KEMH LONG TERM OPTIONS FULL AGONIST PARTIAL
More informationTreatment of Substance Use Disorders in the Real World. Jessica M. Peirce, Ph.D. Johns Hopkins University School of Medicine
Treatment of Substance Use Disorders in the Real World Jessica M. Peirce, Ph.D. Johns Hopkins University School of Medicine Objectives identify the core components of the most common substance use disorder
More informationSubstance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates
Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates What is MAT? Medication Assisted Treatment (MAT) is the use of medications, in addition to counseling, cognitive behavioral
More informationVivitrol/Suboxone. Comparison Study Summary
Vivitrol/Suboxone Comparison Study Summary Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., & King, J. (2017). Comparative effectiveness of extended-release naltrexone versus
More informationIncorporating Alcohol Pharmacotherapies into Medical Practice
Incorporating Alcohol Pharmacotherapies into Medical Practice What Is a TIP? Treatment Improvement Protocols (TIPs), developed by the Center for Substance Abuse Treatment (CSAT), part of the Substance
More informationWISAM 2018 Clinical Workshops September 29, Naltrexone in Treatment for Alcohol. and Practical Applications
Naltrexone in Treatment for Alcohol and Opioid Use Disorders: Case Studies and Practical Applications Aleksandra Zgierska, MD, PhD, DFASAM CAPT Ted L.Hall, PharmD, BCPP, RPh WISAM 2018 Annual Conference:
More informationGUIDELINES FOR THE USE OF PSYCHOACTIVE MEDICATIONS IN INDIVIDUALS WITH CO-OCCURRING SUBSTANCE USE DISORDERS
City and County of San Francisco Mayor Gavin Newsom Department of Public Health Community Behavioral Health Services 1380 Howard Street 5 th Floor San Francisco, CA 94103 GUIDELINES FOR THE USE OF PSYCHOACTIVE
More informationAssociate Medical Director of Addiction Medicine, Summa Physicians Inc., Akron, OH Medical Director Esper Treatment Center, Erie, PA Chief Medical
Associate Medical Director of Addiction Medicine, Summa Physicians Inc., Akron, OH Medical Director Esper Treatment Center, Erie, PA Chief Medical Officer, Interval Brotherhood Home, Akron, OH Director
More informationReducing excessive alcohol use and harm in Alaska.
Reducing excessive alcohol use and harm in Alaska. Medication Assisted Treatment for Alcohol Use Disorder: Current Status and Future Directions Barbara J. Mason, Ph.D. Pearson Family Professor Director,
More informationNIAAA s Medications Development Program to Treat Alcohol Use Disorder: Advances, Goals, and Initiatives
NIAAA s Medications Development Program to Treat Alcohol Use Disorder: Advances, Goals, and Initiatives Raye Z. Litten, Ph.D. Acting Director Division of Medications Development National Institute on Alcohol
More informationInjectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP
Injectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP Overview Gavin Foundation Injectable naltrexone Community report
More informationThe available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines
The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines Background, Objectives and Methods Systematic reviews (SRs) published by Cochrane Drugs
More informationMedication Assisted Treatment:
Medication Assisted Treatment: A Training For Multidisciplinary Addiction Professionals Module III Medications 101 Goals for Module III This module reviews the following: Overview of three medications
More informationKaren F Marlowe, Pharm D, BCPS Certified Pain Educator Auburn University Harrison School of Pharmacy University of South Alabama School of Medicine
Karen F Marlowe, Pharm D, BCPS Certified Pain Educator Auburn University Harrison School of Pharmacy University of South Alabama School of Medicine A 58 year old patient 20 year history of alcohol, opioid
More informationIncorporating Alcohol Pharmacotherapies Into Medical Practice. A Treatment Improvement Protocol TIP
Incorporating Alcohol Pharmacotherapies Into Medical Practice A Treatment Improvement Protocol TIP 49 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration
More informationMichael O Neil, Pharm.D. Professor and Vice-Chair, Department of Pharmacy Practice Drug Diversion, Substance Abuse, and Pain Management Consultant
Michael O Neil, Pharm.D. Professor and Vice-Chair, Department of Pharmacy Practice Drug Diversion, Substance Abuse, and Pain Management Consultant South College School of Pharmacy Knoxville, TN (304) 546-7746
More informationNEUROBIOLOGY ALCOHOLISM
NEUROBIOLOGY ALCOHOLISM THERE HAS BEEN A MAJOR THEORETICAL SHIFT IN MEDICATION DEVELOPMENT IN ALCOHOLISM Driven by animal models of intermittent ethanol administration followed by termination, then access
More information